Zinger Key Points
- Eli Lilly's CEO announced the imminent end of the tirzepatide shortage, impacting the weight-loss drug market and potentially HIMS.
- Hims & Hers Health is set to release its Q2 earnings on August 5th, with expected EPS of 4 cents and revenue of $299.942 million
- Feel unsure about the market’s next move? Copy trade alerts from Matt Maley—a Wall Street veteran who consistently finds profits in volatile markets. Claim your 7-day free trial now.
Hims & Hers Health, Inc. HIMS experienced a significant decline in its stock price on Thursday. Here’s what you need to know.
What To Know: The sharp drop in Hims & Hers Health shares may have been influenced by broader market reactions to news from Eli Lilly and Co LLY regarding the expected end of the shortage of its popular weight-loss drug, tirzepatide, which is marketed as Mounjaro for diabetes and Zepbound for weight management.
Eli Lilly CEO David Ricks announced in an interview with Bloomberg News that the drug shortage will end “very soon.” This development has significant implications for the weight-loss drug market, a sector in which Hims & Hers is also actively involved.
What Else: Additionally, Hims & Hers Health is also set to release its second-quarter earnings report on Monday, Aug. 5, after the market closes. The company is expected to report an estimated EPS of 4 cents and revenue of $299.942 million.
HIMS Price Action: Hims & Hers Health shares fell by 12.6% to $18.57, according to Benzinga Pro.
Now Read:
Image: Courtesy of Hims & Hers Health, Inc.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
